Colorado-based biopharmaceutical company Ananda Scientific and New York University Grossman School of Medicine announced a second clinical trial to evaluate CBD's effects in subjects treating spinal pain with opioids.
Preclinical and initial clinical studies had shown that Ananda's proprietary Liquid Structure™ Cannabidiol formulation could help reduce opioid intake in patients with this chronic pain, improving CBD's efficacy and stability. The investigational new drug was approved by the US Food and Drug Administration (FDA).
Ananda president Sohail R. Zaidi said, “Approval of a second clinical study with a world-renowned institution advances CBD applications using Ananda's patented technology in an area that could positively affect many lives impacted by opioid dependence. Opioids are a leading cause of overdose deaths in the United States, and there is an important need for a non-addictive new treatment.”
The trials are led by Dr. Stephen Ross, associate professor of psychiatry and director of NYU's Addiction Disorders and Experimental Therapeutics Research Laboratory. Funding comes from the National Institute on Drug Abuse, with Ananda Scientific's support.
Dr. Stephen Ross said, “Expanding research into therapeutic alternatives for chronic pain disorders is critical to reversing the opioid epidemic. Ananda's commitment to safe, effective, high-quality products and its groundbreaking delivery technologies create a tremendous opportunity to develop evidence-based CBD medicines to reduce opioid intake and pain. We look forward to collaborating with Ananda in this important clinical trial.”
This is not Ananda Scientific's only medical CBD project. It holds a patent involving CBD and similar cannabinoids to treat deadly cytokine storms caused by COVID-19 and other conditions caused by excessive immune proteins. The company continues working on this potential treatment. Preclinical data had shown that its proprietary Liquid Structure™ Cannabidiol formulation could reduce levels of the immune protein tumor necrosis factor alpha (TNF-a).
